CFA
DTIL icon

Carroll Financial Associates’s Precision BioSciences DTIL Stock Holding History

Carroll Financial Associates’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$4K Hold
20
– – ﹤0.01% 1376
2021
Q3 		$6K Hold
20
– – ﹤0.01% 1336
2021
Q2 		$7K Hold
20
– – ﹤0.01% 1365
2021
Q1 		$6K Buy
+20
New +$7K ﹤0.01% 1330

Other funds holding DTIL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Carroll Financial Associates's DTIL Position: Q4 2021 in Review

Carroll Financial Associates held its Precision BioSciences (DTIL) position steady in Q4 2021 at 20 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #1376.

Carroll Financial Associates first reported a position in DTIL in Q1 2021 and has held it in 4 quarters since. The position peaked at $7K in Q2 2021. 134 funds tracked by Wall St. Rank hold DTIL as of Q4 2021.

  • Carroll Financial Associates held 20 shares of Precision BioSciences worth $4K as of Q4 2021.
  • Carroll Financial Associates left its Precision BioSciences share count unchanged in Q4 2021.
  • Precision BioSciences made up ﹤0.01% of Carroll Financial Associates's portfolio in Q4 2021, its #1376 holding.
  • Carroll Financial Associates first reported a position in Precision BioSciences in Q1 2021 and has held it in 4 quarters since.
  • Carroll Financial Associates's Precision BioSciences position peaked at $7K in Q2 2021.
  • 134 funds tracked by Wall St. Rank held Precision BioSciences as of Q4 2021.

Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.